12:00 AM
 | 
Jan 07, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

OrbeShield regulatory update

Soligenix said FDA granted Orphan Drug designation to OrbeShield to prevent death following a potentially lethal dose of total body irradiation (TBI) during or after a radiation disaster. Soligenix is developing the oral formulation of beclomethasone dipropionate (BDP) under FDA's animal rule,...

Read the full 187 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >